Receive consultations to better support the behavioral health needs of child and adolescent patients

Jul. 2025What's New

The Telephonic Psychiatric Consultation Service Program (TiPS) is a Pennsylvania HealthChoices program that gives primary care providers access to free, on-demand consultations with child and adolescent psychiatrists, typically within 30 minutes. It is available to providers of children and adolescents who have Pennsylvania Medicaid, Children’s Health Insurance Program, or UPMC Health Plan commercial insurance.

Primary care providers can partner with TiPS psychiatrists for telephonic, virtual, and face-to-face consultations. During these sessions, providers can:

  • Receive consultative advice regarding behavioral health concerns in a child up to age 21.
  • Obtain referrals for care coordinators when behavioral health services are needed.
  • Ask general questions related to mental health or substance use, such as those around medications, diagnoses, screening tools, resources, and other topics.

TiPS also offers training and education, including conferences with free CME courses. Click here to reference our TiPS flier.

Contacting TiPS
There is no fee for practices to enroll in TiPS. Please use the appropriate phone number for your designated HealthChoices region to speak to your regional team and get started. You can refer to the DHS TiPs page for additional guidance.

Northwest and Southwest Pennsylvania (Northwest and Southwest zones)
UPMC Children’s Community Pediatrics
Phone: 1-844-WPA-TiPS (1-844-972-8477)

Northeast and Central Pennsylvania (Northeast and Lehigh/Capital zones)
Penn State Health Milton S. Hershey Medical Center
Phone: 1-800-233-4082 (press 3)

Southeast Pennsylvania (Southeast Zone)
Children’s Hospital of Philadelphia
Phone: 267-426-1776


Recent Announcements

CME Webinar: The State of Telehealth in 2026

Please join us for a live, CME-accredited webinar on Tuesday, Jan. 27, from noon to 1 p.m. that will share updates on the state of telehealth for 2026.
Dec. 2025Education/Webinars

Formulary updates effective Jan. 1, 2026

Review upcoming policy and operational updates
Dec. 2025Pharmacy Updates

Voluntary nationwide recall: Famotidine (Fresenius – November)

Fresenius Kabi USA, LLC is recalling three lots (6133156, 6133194, and 6133388) of Famotidine Injection, USP, 20 mg per 2 mL. Famotidine is used to treat excessive secretion of stomach acid or stomach ulcers.
Nov. 2025Pharmacy Updates